BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Marketing Authorization Application (MAA)
Acusphere Inc. (ACUS) Withdraws Its European Marketing Authorization Application For Imagify 8/28/2014
Cubist Pharmaceuticals, Inc. (CBST) Announces European Medicines Agency Acceptance Of Ceftolozane/Tazobactam Marketing Authorization Application For Review 8/22/2014
NovoCure Ltd. Announces The Submission Of A Pre-Marketing Approval Application In Japan For The NovoTTF™-100A System To Treat Recurrent Glioblastoma 8/21/2014
ThromboGenics NV (TBGNF)' JETREA Receives Positive Recommendation From Scottish Medicines Consortium (SMC) 8/11/2014
European Medicines Agency Accepts Application Seeking New Indication For Pfizer Inc. (PFE)'s Prevenar 13®1 For Prevention Of Pneumococcal Pneumonia In Adults 8/7/2014
Insmed Incorporated (INSM) Tanks As Phase 3 Plans Are Needed For ARIKAYCE, Delaying FDA Approval 8/5/2014
PTC Therapeutics, Inc. (PTCT) Receives Conditional Approval In The European Union For Translarna™ For The Treatment Of Nonsense Mutation Duchenne Muscular Dystrophy 8/4/2014
Shares Of Biogen Idec, Inc. (Massachusetts) (BIIB) Slip As Tecfidera Hits Second Hurdle In Germany 8/4/2014
NeuroDerm Ltd. Announces Eligibility For European Union Centralized Procedure For ND0612H, A Novel Treatment For Advanced Parkinson's Disease 8/4/2014
Alimera Sciences (ALIM)' ILUVIEN® Receives Marketing Authorization In Denmark For The Treatment Of Chronic Diabetic Macular Edema 8/1/2014
pSivida Corp (PSDV) Reports ILUVIEN® For Chronic Diabetic Macular Edema Receives Marketing Authorization In Denmark, 9th EU Approval 8/1/2014
Orexigen Therapeutics, Inc. (OREX) Receives CHMP Day 180 List Of Outstanding Issues 7/30/2014
Alimera Sciences (ALIM)' ILUVIEN® Receives Marketing Authorization In Norway For The Treatment Of Chronic Diabetic Macular Edema 7/29/2014
pSivida Corp (PSDV) Announces Iluvien® Receives Marketing Authorization In Norway And Approval For Reimbursement In Portugal 7/29/2014
CHMP Issues Positive Opinion For Roche (RHHBY) RA Drug Label Expansion 7/28/2014
Veloxis Pharmaceuticals A/S (VELO) Release: Envarsus® Receives European Marketing Authorization For Treatment Of Both Kidney And Liver Transplant Patients 7/28/2014
GlaxoSmithKline (GSK) Seeks Approval For First Ever Malaria Vaccination 7/28/2014
European CHMP Adopts Positive Opinion For Gilead Sciences, Inc. (GILD)’s Zydelig® (Idelalisib) For The Treatment Of Chronic Lymphocytic Leukemia And Follicular Lymphoma 7/25/2014
Allergan Inc. (AGN) Announces OZURDEX® (Dexamethasone 700 mcg Intravitreal Implant In Applicator) Receives European Positive Opinion For The Treatment Of Diabetic Macular Edema 7/25/2014
Alexion Pharmaceuticals Inc. (ALXN) Release: European Medicines Agency Accepts Marketing Authorization Application For Asfotase Alfa As A Treatment For Patients With Hypophosphatasia 7/24/2014
Bioniche Life Sciences Inc. (BNC) Announces Intention To File For Marketing Approval Of MCNA In The United States 7/18/2014
Basilea Pharmaceutica (BSLN.SW) Isavuconazole European Marketing Authorization Application For The Treatment Of Invasive Mold Infections 7/17/2014
Shenzhen Beike Biotechnology Co. Ltd. Release: Biotech Company Receives Application Approval From Chinese Food And Drug Administration 7/10/2014
Sigma-Tau Rare Disease Submits Application To The European Medicines Agency For Use Of PegylatedL-Asparaginase (Oncaspar®) In The Treatment Of Acute Lymphoblastic Leukaemia 7/10/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces European Medicines Agency Acceptance Of Pediatric Investigation Plan For Qinprezo™ (Vosaroxin) For AML 7/9/2014
The Medicines Company (MDCO) Receives Market Authorization Renewal For Angiox® (Bivalirudin) From The European Medicines Agency And The European Commission 7/7/2014
AcelRx Pharmaceuticals (ACRX) And Grunenthal Announce Submission Of European Marketing Authorization Application For ZALVISO™ 7/7/2014
Teva Pharmaceutical Industries Limited (TEVA) Receives CHMP Positive Opinion For Seasonique® Extended-Regimen Contraceptive For Marketing Authorization In Several European Countries 7/7/2014
GlaxoSmithKline (GSK) And Genmab A/S (GEN.CO) Receive EU Authorization For Arzerra™ (Ofatumumab) As First-Line Treatment For Chronic Lymphocytic Leukemia (CLL) In Combination With Chlorambucil Or Bendamustine For Patients Ineligible For Fludarabine-Based Therapy 7/3/2014
Boehringer Ingelheim Corporation Submits Applications In Europe For Tiotropium + Olodaterol Respimat® Fixed-Dose Combination In COPD 7/2/2014
pSivida Corp (PSDV) Reports Positive Regulatory Outcome For Iluvien®; Moves To National Phase For Marketing Authorizations In 10 More EU Countries 7/1/2014
Ipsen (IPN.PA) Submits Marketing Authorization Applications In The U.S. And Europe For Somatuline® (Lanreotide) In The Treatment Of Gastroenteropancreatic Neuroendocrine Tumors (GEP-Nets) 7/1/2014
TiGenix Release: European Medicines Agency Renews Marketing Authorization For Chondrocelect 7/1/2014
MSD’s Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review In Europe For The Treatment Of Advanced Melanoma 6/30/2014
GE Healthcare Release: CHMP Recommends EU Approval Of VIZAMYL™ (Flutemetamol F18 Injection) For PET Imaging Of Beta Amyloid Plaque 6/30/2014
Bristol-Myers Squibb Company (BMY), Pfizer Inc. (PFE)'s Clot Drug Eliquis® Gets EU Green Light For Wider Use 6/27/2014
Vertex Pharmaceuticals (MA) (VRTX) Grabs EU Recommendation For KALYDECO™ (Ivacaftor) In Eight Non-G551D Gating Mutations 6/27/2014
Bristol-Myers Squibb Company (BMY)'s Hepatitis C Drug Daklinza Receives Positive CHMP Opinion 6/27/2014
Janssen-Cilag International NV (JNJ) Submits EU Marketing Application For VELCADE® (Bortezomib) In Mantle Cell Lymphoma 6/27/2014
Roche (RHHBY)'s Avastin: First Biologic Backed In EU For Resistant Ovarian Cancer 6/27/2014
Regeneron Pharmaceuticals, Inc. (REGN)'s Injection Eylea Recommended For Approval By CHMP 6/27/2014
Eli Lilly and Company (LLY), Boehringer Ingelheim Corporation Win EU Backing For Copy Of Sanofi (France) (SAN.PA)'s Top Insulin Lantus 6/27/2014
Eisai Company, Ltd. (ESALY.PK) Submits First Marketing Authorization Application For Anticancer Agent Lenvatinib In Japan 6/27/2014
Hyperion Therapeutics Announces European Medicines Agency Acceptance For Review Of Marketing Authorization Application For RAVICTI® 6/26/2014
BioSpecifics Technologies Corporation (BSTC) Announces Filing By Swedish Orphan Biovitrum For EU Approval Of XIAPEX For Peyronies Disease 6/26/2014
Auxilium Pharmaceuticals (AUXL) Release: Swedish Orphan AB Files For EU Approval Of Xiapex For Peyronies Disease 6/25/2014
Alimera Sciences (ALIM)' ILUVIEN® Receives Marketing Authorization In Italy For The Treatment Of Chronic Diabetic Macular Edema 6/23/2014
pSivida Corp (PSDV) Announces ILUVIEN® Receives Marketing Authorization In Italy For Treatment Of Chronic Diabetic Macular Edema 6/23/2014
Enanta Pharmaceuticals, Inc. Announces European Medicines Agency Validates Marketing Authorization Applications For AbbVie (ABBV)’s Investigational, All-Oral, Interferon-Free Regimen For Genotype 1 Chronic Hepatitis C 6/17/2014
European Medicines Agency Validates Marketing Authorization Applications For AbbVie (ABBV)'s Investigational, All-Oral, Interferon-Free Therapy For The Treatment Of Genotype 1 Chronic Hepatitis C 6/17/2014
Regeneron Pharmaceuticals, Inc. (REGN) Release: EYLEA® (Aflibercept) Injection Submitted For EU Marketing Authorization For The Treatment Of Patients With Macular Edema Secondary To Branch Retinal Vein Occlusion (BRVO) 6/11/2014
European Medicines Agency Accepts Boehringer Ingelheim Corporation's Marketing Authorization Application For Nintedanib For IPF 6/5/2014
Vanda Pharmaceuticals, Inc. (VNDA) Release: European Medicines Agency Accepts HETLIOZ™ (Tasimelteon) Marketing Authorization Application For Non-24-Hour Sleep-Wake Disorder In The Totally Blind 6/3/2014
Protein Sciences Corporation Partners File For Marketing Approval Of Flublok® Influenza Vaccine In Japan 6/2/2014
EU Changes Its Tune On PTC Therapeutics, Inc. (PTCT) Drug, Shares Rocket 30.74% At Market Close (May 23, 2014) 5/27/2014
Eisai Company, Ltd. (ESALY.PK) Receives Positive Opinion From European Medicines Agency's CHMP On Expanding 5/27/2014
GlaxoSmithKline (GSK) And Genmab A/S (GEN.CO) Receive CHMP Positive Opinion For Arzerra™ In Combination With Chlorambucil Or Bendamustine As A First-Line Treatment For Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Not Eligible For Fludarabine-Based Therapy 5/23/2014
CHMP Adopts Positive Opinion For Biogen Idec, Inc. (Massachusetts) (BIIB)'s PLEGRIDY™ (Peginterferon Beta-1a) As A Treatment For Multiple Sclerosis In The European Union 5/23/2014
European Medicines Agency Recommends Approval Of Roche (RHHBY)'s Gazyvaro For Chronic Lymphocytic Leukaemia 5/23/2014
Despite Rejection, Teva Pharmaceutical Industries Limited (TEVA) And Active Biotech AB (BTPC) Remain Committed To The Development Of Multiple Sclerosis Nerventra® 5/23/2014
Veloxis Pharmaceuticals A/S (VELO) Receives Positive Opinion From CHMP For Envarsus® For Treatment Of Both Kidney And Liver Transplant Patients 5/22/2014
Merck & Co., Inc. (MRK), Endocyte, Inc. (ECYT) Withdraw Marketing Applications For Ovarian Cancer Drug 5/21/2014
Janssen-Cilag International NV (JNJ) Release: OLYSIO™ (Simeprevir) Receives Marketing Authorization In The European Union For The Treatment Of Adults With Hepatitis C Genotype 1 And 4 Infection 5/16/2014
Enanta Pharmaceuticals, Inc. Announces Submission Of EU Marketing Authorization Applications To European Medicines Agency For All-Oral, Interferon-Free Hepatitis C Regimen Containing ABT-450 5/8/2014
AbbVie (ABBV) Submits For EU Marketing Authorization Its Investigational, All-Oral, Interferon-Free Therapy For The Treatment Of Chronic Hepatitis C 5/8/2014
Theravance, Inc. (THRX) Release: Anoro® (Umeclidinium/Vilanterol) Gains Marketing Authorization in Europe For The Treatment Of COPD 5/8/2014
Pierre Fabre Obtains European Commission Marketing Authorization For Hemangiol®, The First And Only Drug Approved For The Treatment Of Proliferating Infantile Hemangioma 5/5/2014
Orion Corporation Receives First Marketing Authorisations For Bufomix Easyhaler® Product 4/15/2014
RedHill Biopharma Ltd. (RDHL) Announces Positive European Scientific Advice Meeting Regarding RHB-102 And Plans To Submit A European Marketing Application 4/7/2014
Newron Pharmaceuticals (NWRN) Release: Safinamide Application For Authorization Submitted To Swissmedic 4/7/2014
Keryx Biopharmaceuticals (KERX) Announces European Medicines Agency Validation Of Marketing Authorization Application For Zerenex™ 4/2/2014
European Medicines Agency Validates Gilead Sciences, Inc. (GILD)’s Marketing Application For Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet For Genotype 1 Chronic Hepatitis C Infection 3/28/2014
Shire Submits INTUNIV (Guanfacine Extended Release) Marketing Authorisation Application To European Medicines Agency 3/27/2014
GlaxoSmithKline (GSK) Melanoma Drug Combination Faces Delay In Europe 3/26/2014
Medivir AB (MVRBF): Simeprevir Receives Positive CHMP Opinion For The Treatment Of Adults With Chronic Hepatitis C In The European Union 3/21/2014
Merck & Co., Inc. (MRK), Endocyte, Inc. (ECYT) Cancer Products Get Thumbs Up From EU Committee CHMP 3/21/2014
Navidea Biopharmaceuticals (NAVB) Provides Update On European Marketing Authorization Application For Lymphoseek® 3/20/2014
Keryx Biopharmaceuticals (KERX) Announces Submission Of A Marketing Authorization Application For Zerenex™ To The European Medicines Agency 3/10/2014
Bayer HealthCare (BAY) And Regeneron Pharmaceuticals, Inc. (REGN) Announce Regulatory Submission Of EYLEA® (Aflibercept) Injection For The Treatment Of Diabetic Macular Edema In Japan 3/3/2014
CHMP Issues Positive Opinion For Tablet Formulation Of Merck & Co., Inc. (MRK)’s NOXAFIL® (posaconazole) 2/28/2014
Cubist Pharmaceuticals, Inc. (CBST) Announces European Medicines Agency Acceptance Of Tedizolid Marketing Authorization Application For Review 2/27/2014
European Medicines Agency Accepts Marketing Authorization Application For The Medicines Company (MDCO)'s Oritavancin 2/27/2014
Janssen-Cilag International NV (JNJ) Release: VOKANAMET™ (Canagliflozin And Metformin Fixed Dose Combination) Receives Positive CHMP Opinion Recommending Approval In The European Union For The Treatment Of Adults With Type 2 Diabetes[1] 2/21/2014
Teva Pharmaceutical Industries Limited (TEVA) Receives CHMP Positive Opinion For Duoresp® Spiromax® For The Treatment Of Patients Diagnosed With Asthma And COPD In Europe 2/21/2014
GlaxoSmithKline (GSK)'s Anoro® (umeclidinium / vilanterol) Receives Positive Opinion From The CHMP In Europe For The Treatment Of COPD 2/20/2014
BioMarin Pharmaceutical Inc. (BMRN) Receives Positive Opinion From The CHMP In The European Union For VIMIZIM™ (Elosulfase Alfa) For Morquio A Syndrome 2/20/2014
Shire plc Submits Elvanse® (Lisdexamfetamine Dimesylate) For An Adult Licence In The UK, Denmark And Sweden 2/19/2014
Dynavax Technologies Corporation (DVAX) Announces Withdrawal Of European Marketing Application For HEPLISAV™ 2/18/2014
MSD Animal Health Receives Marketing Authorization From European Commission for BRAVECTO™ (fluralaner) 2/17/2014
Vectura Group plc (VEC.L): Belgian Regulatory Authority Confirm Approval Of AirFluSal® Forspiro® 2/12/2014
Arena Pharmaceuticals, Inc. (ARNA) Announces Filing For Marketing Authorization Of BELVIQ® (lorcaserin HCl) In Brazil 2/12/2014
Vectura Group plc (VEC.L): Bulgarian Regulatory Authority Confirm Approval Of Airflusal® Forspiro® 2/4/2014
XBiotech USA, Inc. And European Medicines Agency Agree On Phase III Registration Study For Treatment Of Colorectal Cancer 1/30/2014
Vectura Group plc (VEC.L) Romanian Regulatory Authority Confirm Approval Of Airflusal® Forspiro® 1/29/2014
Sinovac Biotech Ltd. (SVA) Files Clinical Trial Application With CFDA For Its Proprietary Vaccine Against Avian Influenza A(H7N9) Virus 1/29/2014
Novartis AG (NVS)'s Potential Blockbuster Serelax Suffers Huge Setback 1/27/2014
Endocyte, Inc. (ECYT) Provides Update On CHMP Review Of Pending EU Conditional Marketing Authorization Applications For Vintafolide And Etarfolatide 1/24/2014
PTC Therapeutics, Inc. (PTCT) Slammed As EU Panel Recommends Against Muscular Disorder Drug 1/24/2014
Teva Pharmaceutical Industries Limited (TEVA), Active Biotech AB (BTPC)'s NERVENTRA® Fails To Win European Medicines Agency Backing; Both Companies Remain Committed To The Drug 1/24/2014
FINOX Biotech Release: CHMP Adopts Positive Opinion For BEMFOLA® For Treatment Of Infertility 1/23/2014
Skyepharma PLC (SKYEF) Release: Positive Step Towards Marketing Authorisation For Flutiform® In Spain 1/22/2014
Europe Approves Gilead Sciences, Inc. (GILD)'s Hot, New Hepatitis C Pill 1/20/2014
Cytonet GmbH & Co. KG Submits European Approval Application For Liver Cell Therapy To Treat Urea Cycle Disorders In Children 1/16/2014
European Medicines Agency Accepts Marketing Authorization Application For Biovest International, Inc.’s Cancer Vaccine For Treatment Of Non-Hodgkin’s Follicular Lymphoma 1/13/2014
Bristol-Myers Squibb Company (BMY) Release: Daclatasvir Marketing Authorization Application For Treatment Of Chronic Hepatitis C Validated For Accelerated Regulatory Review By European Medicines Agency 1/8/2014
Daiichi Sankyo, Inc. (4568.t) Submits Edoxaban Marketing Authorization Application To The EMA For Once-Daily Use For Stroke Prevention In Atrial Fibrillation And For The Treatment And Prevention Of Recurrence Of Venous Thromboembolism 1/7/2014
European Medicines Agency Accepts Otsuka America Pharmaceutical, Inc.'s Marketing Authorisation Application (MAA) For Tolvaptan, An Investigational Compound For Autosomal Dominant Polycystic Kidney Disease (ADPKD) 12/27/2013
European Medicines Agency Accepts Marketing Authorization Application For Durata Therapeutics, Inc.  (DRTX)'s Dalbavancin 12/23/2013
European Medicines Agency Postpones Decision On Teva Pharmaceutical Industries Limited (TEVA)'s MS Pill Laquinimod 12/23/2013
European Medicines Agency Accepts Marketing Authorization Application For The Medicines Company (MDCO)'s Cangrelor 12/23/2013
Active Biotech AB (BTPC) Release: Laquinimod CHMP/European Medicines Agency Opinion 12/20/2013
Apricus Biosciences (APRI) Announces National Phase Approval For Erectile Dysfunction Cream - Vitaros® In France 12/20/2013
Navidea Biopharmaceuticals (NAVB) Release: European Medicines Agency Continues Marketing Authorization Application (MAA) Review For Lymphoseek® 12/20/2013
Recipharm AB Subsidiary Files Infectious Disease Drug Application In European Markets Drug Product Developed Through Partnership With Astimex Pharma AB 12/16/2013
U.K. Cost Agency Seeks More Lemtrada Data From Sanofi (France) (SAN.PA) 12/5/2013
Newron Pharmaceuticals (NWRN) Release: Safinamide Marketing Authorization Application (MAA) Submitted To The European Medicines Agency 12/5/2013
Protectimmun Gets Positive Scientific Advice Response From European Medicines Agency For Innovative Allergy Prophylaxis 12/3/2013
Durata Therapeutics, Inc.  (DRTX) Submits Marketing Authorization Application For Dalbavancin 12/3/2013
CHMP Recommends Otsuka Pharmaceutical Co., Ltd.'s Deltyba™ (Delamanid) For EU Approval For Treatment Of Multidrug-Resistant Tuberculosis (MDR-TB) In Combination With Optimized Background Regimen (OBR) 11/25/2013
Celgene International Sárl (CELG) Receives Positive CHMP Opinion For ABRAXANE® In Combination With Gemcitabine As Treatment For Patients With Metastatic Pancreatic Cancer 11/22/2013
European Medicines Agency Accepts Marketing Authorization Application For The Medicines Company (MDCO)'s Fibrocaps Hemostatic Agent 11/22/2013
Biogen Idec, Inc. (Massachusetts) (BIIB) Release: CHMP Determines Dimethyl Fumarate In TECFIDERA® To Be A New Active Substance In The European Union 11/22/2013
European CHMP Adopts Positive Opinion for Gilead Sciences, Inc. (GILD)’ Sovaldi® For The Treatment Of Chronic Hepatitis C Infection 11/22/2013
AstraZeneca PLC (AZN) And Bristol-Myers Squibb Company (BMY) Release: Xigduo™ (Dapagliflozin And Metformin Hydrochloride) Receives Positive CHMP Opinion In The European Union For The Treatment Of Type 2 Diabetes 11/22/2013
ViiV Healthcare Release: Tivicay® (dolutegravir) Receives Positive CHMP Opinion In Europe For The Treatment Of HIV 11/22/2013
Ariad Pharmaceuticals, Inc. (ARIA) Announces Positive Opinion By The European Medicines Agency On The Continued Availability Of Iclusig In Patients With Leukaemias 11/22/2013
RedHill Biopharma Ltd. (RDHL) Announces Positive Scientific Advice Meeting And European Marketing Application Strategy For RHB-103 (Migraine) 11/18/2013
Boehringer Ingelheim Corporation Submits Applications In Europe To Extend The Indication For The Use Of Tiotropium Respimat® To The Treatment Of Asthma In Adults Aged 18 Years And Over 11/13/2013
Bayer AG (BAYN.DE) Submits VEGF Trap-Eye (aflibercept solution for injection) for Treatment of Diabetic Macular Edema in the EU 11/7/2013
Janssen-Cilag International NV (JNJ) Release: New Marketing Authorisation Application Submitted to European Medicines Agency for Ibrutinib for the Treatment of Two Forms of Blood Cancer 10/30/2013
Actelion Ltd. (ALIOF.PK) and Lundbeck Inc. (LUN.CO) Get Positive CHMP Opinions 10/28/2013
H. Lundbeck A/S (LUN.CO) Receives Positive Opinion for Approval of Brintellix (Vortioxetine) in the European Union 10/25/2013
Gentium S.p.A. Receives Marketing Authorization From the European Commission (EC) for Defitelio® (Defibrotide) 10/22/2013
Janssen-Cilag International NV (JNJ) Submits Marketing Authorisation Application to European Medicines Agency for a Fixed-Dose Combination Tablet of HIV-1 Medicine Darunavir With Cobicistat 10/15/2013
Boehringer Ingelheim Corporation Submits Nintedanib, a Novel Oncology Compound, for European Approval 10/14/2013
Gentium S.p.A. Receives Positive Opinion From European Medicines Agency's COMP for Defibrotide for the Prevention of GvHD 10/11/2013
GlaxoSmithKline (GSK) and Genmab A/S (GEN.CO) Announce European Submission to Regulatory Authorities for Arzerra® (Ofatumumab) as 1st Line Treatment of Chronic Lymphocytic Leukemia (CLL) 10/4/2013
Orexigen Therapeutics, Inc. (OREX) Submits Contrave Marketing Authorization Application to European Medicines Agency 10/3/2013
Omeros Corporation (OMER) Release: U.S. and European Regulators Accept for Review OMS302 Marketing Applications 10/2/2013
Nektar Therapeutics (CA) (NKTR) Reports that Partner AstraZeneca PLC (AZN) Announced European Medicines Agency Acceptance of Marketing Authorisation Application for Naloxegol 9/30/2013
Ligand Pharmaceuticals Inc. (LGND) Partner GlaxoSmithKline (GSK) Receives Marketing Authorization From the European Commission (EC) for Additional Revolade™ (Eltrombopag) Indication as the First Approved Treatment for Chronic Hepatitis C-Associated Thrombocytopenia 9/24/2013
Furiex Pharmaceuticals, Inc. (FURX) Confirms Takeda Pharmaceutical Co. Ltd. (TKPYY) Receives European Marketing Authorization for VIPIDIA™ (alogliptin), VIPDOMET™ (alogliptin and metformin) and INCRESYNC™ (alogliptin and pioglitazone) 9/24/2013
Xofigo® (radium Ra 223 dichloride) Injection Recommended for Approval in the European Union 9/20/2013
Otsuka Pharmaceutical Co., Ltd. and Lundbeck Inc. (LUN.CO) Receive Positive CHMP Opinion in Europe for Abilify Maintena™, a Once-Monthly Injectable for Schizophrenia 9/20/2013
Novo Nordisk A/S (NVO) Hemophilia-A Treatment Wins EU Panel Backing 9/20/2013
Dendreon Corporation (DNDN) Announces Marketing Authorization for PROVENGE® in the European Union 9/17/2013
Swissmedic Accepts for Review Basilea Pharmaceutica (BSLN.SW)'s Ceftobiprole Marketing Authorization Application for the Treatment of Pneumonia 9/16/2013
Raptor Pharmaceutical Inc. (RPTP) Receives Marketing Authorization for PROCYSBI® in European Union 9/12/2013
NanoViricides, Inc. (NNVC.PK) Reports That the DengueCide™ Orphan Drug Application has Been Submitted and Received by the European Medicines Agency 9/3/2013
Apricus Biosciences (APRI) Receives National Phase Approvals for Vitaros® in Ireland and the Netherlands 8/15/2013
Teva Pharmaceutical Industries Limited (TEVA) Receives European Marketing Authorization for Lonquex® (XM22 lipegfilgrastim) 8/8/2013
Bavarian Nordic (BAVA.CO) Receives European Marketing Authorization for IMVANEX Smallpox Vaccine 8/7/2013
Skyepharma PLC (SKYEF) Release: flutiform® Recommended for Approval in Japan 7/31/2013
First in Class Once-Daily Dual Bronchodilator Ultibro® Breezhaler® (QVA149) Gains Positive CHMP Opinion for the Treatment of COPD 7/29/2013
CHMP Confirms Prior Opinion Regarding Marketing Authorization in Europe for Pfizer Inc. (PFE)'s XELJANZ® (tofacitinib citrate) 7/26/2013
Regeneron Pharmaceuticals, Inc. (REGN) Release: EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion in Europe 7/26/2013
Merck & Co., Inc. (MRK) Statement Regarding CHMP Review of Incretin-Based Therapies for Type 2 Diabetes, Including Sitagliptin 7/26/2013
Otsuka Pharmaceutical Co., Ltd. Receives Opinion From CHMP on Delamanid 7/26/2013
Ligand Pharmaceuticals Inc. (LGND) Partner GlaxoSmithKline (GSK) Receives Positive CHMP Opinion for REVOLADE™ in Thrombocytopenia Associated with Chronic Hepatitis C Infection 7/26/2013
Boehringer Ingelheim Corporation's Afatinib Receives Positive CHMP Opinion for Patients With EGFR Mutation Positive Lung Cancer in European Union 7/26/2013
Furiex Pharmaceuticals, Inc. (FURX) Confirms Takeda Pharmaceutical Co. Ltd. (TKPYY) Receives Positive CHMP Opinion for VIPIDIA™ (alogliptin) and Fixed-Dose Combinations VIPDOMET™ (alogliptin and metformin) and INCRESYNC™ (alogliptin and pioglitazone) 7/26/2013
Gentium S.p.A. Receives Positive Opinion From European Medicines Agency's CHMP for Defitelio 7/26/2013
Novartis AG (NVS) Vaccine Division Hit by Bexsero Setback 7/24/2013
NanoViricides, Inc. (NNVC.PK) Receives Notification That Clinical Coordinators Have Been Appointed by the European Medicines Agency to Review the Company's Upcoming DengueCide Orphan Drug Designation Application 7/22/2013
Biological E. Limited's Japanese Encephalitis Vaccine Prequalified by the World Health Organization 7/22/2013
Biogen Idec, Inc. (Massachusetts) (BIIB) Release: US and EU Regulatory Authorities Accept PLEGRIDY™ (peginterferon beta-1a) Marketing Applications for Review 7/19/2013
Alexion Pharmaceuticals Inc. (ALXN)'s Soliris® (eculizumab) Receives Positive Opinion From the Committee for Orphan Medicinal Products for Treatment of Neuromyelitis Optica (NMO) 7/16/2013
Eli Lilly and Company (LLY) and Boehringer Ingelheim Corporation Announce Regulatory Submission for New Insulin Glargine Biosimilar Product 7/10/2013
European Medicines Agency Approves Positive Opinion on Omeros Corporation (OMER)' Pediatric Investigation Plan for OMS302 7/2/2013
Emergent BioSolutions (EBS) Receives Paul-Ehrlich-Institut Approval to Market BioThrax in Germany 7/1/2013
First Copy of Johnson & Johnson (JNJ)'s $6 Billion Remicade Wins European Medicines Agency Backing 6/28/2013
CHMP Gives a Positive Opinion for the Use of Janssen-Cilag International NV (JNJ)'s VELCADE® as Retreatment and for Frontline Induction Therapy Before Stem Cell Transplantation 6/28/2013
Halozyme Therapeutics, Inc. (HALO) Announces Positive Opinion From CHMP on Roche (RHHBY)'s Herceptin SC for European Approval 6/28/2013
Raptor Pharmaceutical Inc. (RPTP)'s PROCYSBI™ Receives Positive Recommendation From CHMP 6/28/2013
Genzyme Corporation (GENZ) Receives Positive CHMP Opinion for LEMTRADA™ (alemtuzumab) in Europe 6/28/2013
Dendreon Corporation (DNDN) Surges After Cancer Drug Gets European Backing, Stock Up +0.1701 (4.17%) @10:07 AM ET 6/28/2013
Sanofi (France) (SAN.PA)'s MS Drugs Get Double Boost in Europe 6/28/2013
Valneva Release: ACIP Unanimously Votes to Extend the Recommendations for Use of IXIARO® Vaccine 6/21/2013
Immune Response BioPharma to Seek Approval of REMUNE With MCC of South Africa 6/18/2013
Cangene Corporation (CC:CNJ) Withdraws MAA for Investigational Hemophilia Compound 6/14/2013
Alimera Sciences (ALIM) Announces Issuance of a Positive Appraisal Recommendation on ILUVIEN® for Consultation in the United Kingdom 6/14/2013
pSivida Corp (PSDV) Announces UK's National Institute for Clinical Excellence (NICE) Says Yes to ILUVIEN® in Some Patients With Diabetic Macular Edema in New Draft Guidance 6/13/2013
ThromboGenics NV (TBGNF)' JETREA® Receives Positive Initial National Institute for Clinical Excellence (NICE) Recommendation for Vitreomacular Traction and Macular Hole 6/12/2013
Gentium S.p.A. Provides Update on Re-Examination of Defibrotide MAA to EMA 6/4/2013
Teva Pharmaceutical Industries Limited (TEVA)'s Lonquex®(XM22 lipegfilgrastim) Recommended for Approval in the EU for the Reduction of Chemotherapy-Induced Neutropenia (CIN) 6/3/2013
European Medicines Agency Recommends Approval of Aegerion Pharmaceuticals, Inc. (AEGR)'s Pomalidomide for the Treatment of Multiple Myeloma 5/31/2013
Bavarian Nordic (BAVA.CO)'s IMVANEX® Smallpox Vaccine Receives Positive Opinion From European Regulatory Authorities 5/31/2013
BioPartners GmbH Release: Positive CHMP Opinion for Once-Weekly Somatropin Biopartners 5/31/2013
Novo Nordisk A/S (NVO) Files for Regulatory Approval of IDegLira in the EU for the Treatment of Type 2 Diabetes 5/31/2013
Oral Anti-Cancer Therapy Pomalidomide Celgene International Sárl (CELG) Receives Positive CHMP Opinion as Treatment for Patients With Relapsed and Refractory Multiple Myeloma 5/31/2013
EU Agency Calls for Curbs on GlaxoSmithKline (GSK), Valeant Pharmaceuticals International (VRX) Epilepsy Drug 5/31/2013
AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) (AVEO) Drops as Astellas Pharma Inc. (YPH.BE) Will Not Seek Nod for Kidney Cancer Drug 5/28/2013
Astellas Pharma Inc. (YPH.BE) and Medivation, Inc. (MDVN) Announce Submission of Application for Marketing Approval of Enzalutamide, an Oral Androgen Receptor Inhibitor, in Japan 5/24/2013
European Medicines Agency Accepts Veloxis Pharmaceuticals A/S (VELO)' Marketing Authorization Application (MAA) for LCP-Tacro for Treatment of Kidney Transplant Patients 5/22/2013
European Medicines Agency Validates Gilead Sciences, Inc. (GILD)'s Marketing Application for Sofosbuvir for the Treatment of Hepatitis C 5/22/2013
Baxter International, Inc. (BAX) Receives Marketing Authorization for HyQvia in European Union 5/21/2013
Arena Pharmaceuticals, Inc. (ARNA) Withdraws Diet Drug Application in Europe 5/3/2013
Omeros Corporation (OMER) Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review 4/30/2013
Veloxis Pharmaceuticals A/S (VELO) Announces Submission of Marketing Authorization Application (MAA) to European Medicines Agency (EMA) for LCP-Tacro™ for Treatment of Kidney Transplant Patients 4/29/2013
Pfizer Inc. (PFE)'s Arthritis Drug Rejected by European Regulators 4/29/2013